Neogenix Oncology, Inc.: Chapter 11 case summary
ElevenFlo ·
Neogenix’s liquidation plan became effective by July 2016, and the court entered a final decree Dkt. 686 on March 9, 2020. No further material milestone is identified in the case filings summarized here.
Neogenix Oncology’s Chapter 11 case proceeded under a confirmed liquidation plan that had become effective by July 6, 2016, as reported in the confirmation and effectiveness notice Dkt. 608. The court entered a final decree Dkt. 686 on March 9, 2020.
Neogenix filed for Chapter 11 on July 23, 2012. The clinical-stage biotechnology company had no commercialized products and faced difficulty raising capital after an SEC inquiry into finder fees paid to unlicensed brokers; potential shareholder rescission claims added to the pressure. Its first-day declaration Dkt. 5 reported a $640,697.00 prepetition bridge loan from Precision Biologics and described a proposed asset sale to that company.
The court subsequently authorized postpetition financing and repayment of the prepetition loan in a final financing order Dkt. 137, and approved an asset purchase agreement and sale of certain assets in a sale order Dkt. 176. Neogenix later pursued the second amended liquidation plan Dkt. 573 that became effective in 2016.
Sources
- Dkt. 5First Day DeclarationFiled Jul 24, 2012Jul 24, 2012
- Dkt. 137Final Order (A) Authorizing the Debtor to Incur Postpetition Financing; (B) Granting Certain Liens, Security Interest, Superpriority Claims and Other Relief to Precision Biologics, Inc. as DIP Lender; (C) Authorizing the Repayment of the Prepetition Loan Obligations in Full and (D) Granting Related ReliefFiled Aug 24, 2012Aug 24, 2012
- Dkt. 176Order (I) Approving Asset Purchase Agreement and Authorizing the Sale of Certain Assets of Debtor Outside the Ordinary Course of Business, (II) Authorizing the Sale of Assets Free and Clear of All Liens, Claims,Encumbrances and Interests, (III) Authorizing the Assumption, Sale and Assignment of Certain Executory Contracts and Unexpired Leases, and (IV) Granting Related ReliefFiled Sep 20, 2012Sep 20, 2012
- Dkt. 573Neogenix Oncology, Inc.’s Second Amended Plan of LiquidationFiled Mar 17, 2016Mar 17, 2016
- Dkt. 608Notice of (I) Confirmation of Neogenix Oncology, Inc.'s Second Amended Plan of Liquidation Under Chapter 11 of the Bankruptcy Code, (II) the Occurrence of the Effective Date, and (III) the Deadlines for Filing Administrative Expense Claims, Rejection Damages Claims, and Final Fee ApplicationsFiled Jul 6, 2016Jul 6, 2016
- Dkt. 686Final DecreeFiled Mar 9, 2020Mar 9, 2020